Contact

All Stories

  1. Interpreting results from biomarker-guided clinical trials: avoiding “negative” or “failed” terminology

    Article • BMC Medicine, May 2025, Springer Science + Business Media

    Dr Joshua S Savage

  2. Selumetinib in Combination with Anti Retroviral Therapy in HIV-associated Kaposi sarcoma (SCART): an open-label, multicentre, phase I/II trial

    Article • BMC Cancer, March 2025, Springer Science + Business Media

    Dr Joshua S Savage

  3. A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer

    Article • npj Precision Oncology, March 2025, Springer Science + Business Media

    Dr Joshua S Savage

  4. Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancer

    Article • BJC Reports, January 2024, Springer Science + Business Media

    Dr Joshua S Savage

  5. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial

    Article • BMC Cancer, January 2024, Springer Science + Business Media

    Dr Joshua S Savage

  6. Abstract A115: mTOR targeting in STK11 deficient Non-Small Cell Lung Cancer (NSCLC): final results, pre-clinical rationale and biomarker analysis of a phase II trial of the mTORC1/2 inhibitor vistusertib in STK11 deficient lung adenocarcinoma (NLMT B2)

    Article • Molecular Cancer Therapeutics, December 2023, American Association for Cancer Research (AACR)

    Dr Joshua S Savage

  7. The MEK Inhibitor Selumetinib in Combination with Dexamethasone Leads to Responses in Adult and Pediatric Patients with Relapsed RAS-Pathway Mutated Acute Lymphoblastic Leukemia: Results of a Phase 1/2 Study

    Article • Blood, November 2023, American Society of Hematology

    Dr Joshua S Savage

  8. MA06.06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J

    Article • Journal of Thoracic Oncology, November 2023, Elsevier

    Dr Joshua S Savage

  9. TESSA JOWELL BRAIN MATRIX PLATFORM STUDY: PRELIMINARY ANALYSIS OF THE PRIMARY FEASIBILITY & PROCESS-CENTRED OBJECTIVE

    Article • Neuro-Oncology, September 2023, Oxford University Press (OUP)

    Dr Joshua S Savage

  10. Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information

    Article • Journal of Clinical Epidemiology, October 2022, Elsevier

    Dr Joshua S Savage

  11. Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

    Article • Trials, September 2022, Springer Science + Business Media

    Dr Joshua S Savage, Mrs Annabelle South

  12. Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

    Article • BMJ Open, September 2022, BMJ

    Dr Joshua S Savage

  13. 426P Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial

    Article • Annals of Oncology, September 2022, Elsevier

    Dr Joshua S Savage

  14. Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

    Article • July 2022, Cold Spring Harbor Laboratory Press

    Dr Joshua S Savage

  15. Clinical trial management: a profession in crisis?

    Article • Trials, April 2022, Springer Science + Business Media

    Dr Joshua S Savage

  16. Practical Guidance for Running Late-Phase Platform Protocols for Clinical Trials: Lessons From Experienced UK Clinical Trials Units

    Article • March 2022, Research Square

    Dr Joshua S Savage

  17. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion ph...

    Article • BMJ Open, March 2022, BMJ

    Dr Joshua S Savage

  18. Subgroup Analyses in Randomised Controlled Trials Frequently Categorise Continuous Subgroup Information

    Article • SSRN Electronic Journal, January 2022, Elsevier

    Dr Joshua S Savage

  19. CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

    Article • BMJ Open, November 2021, BMJ

    Dr Joshua S Savage

  20. Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion ph...

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Dr Joshua S Savage

  21. CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

    Article • February 2021, Cold Spring Harbor Laboratory Press

    Dr Joshua S Savage

  22. The National Lung Matrix Trial of personalized therapy in lung cancer

    Article • Nature, July 2020, Springer Science + Business Media

    Dr Joshua S Savage

  23. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial

    Article • The Lancet Respiratory Medicine, March 2020, Elsevier

    Dr Joshua S Savage

  24. Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol

    Article • BMJ Open, March 2020, BMJ

    Dr Joshua S Savage

  25. PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC)

    Article • Journal of Thoracic Oncology, October 2019, Elsevier

    Dr Joshua S Savage

  26. 1384PDPembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial

    Article • Annals of Oncology, October 2018, Oxford University Press (OUP)

    Dr Joshua S Savage

  27. UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

    Article • Journal of Clinical Oncology, May 2016, American Society of Clinical Oncology (ASCO)

    Dr Joshua S Savage

  28. Identification of roles for the SNARE-associated protein, SNAP29, in mouse platelets

    Article • Platelets, November 2015, Taylor & Francis

    Dr Joshua S Savage

  29. Syntaxin 8 Regulates Platelet Dense Granule Secretion, Aggregation, and Thrombus Stability

    Article • Journal of Biological Chemistry, November 2014, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Joshua S Savage

  30. RhoG Protein Regulates Platelet Granule Secretion and Thrombus Formation in Mice

    Article • Journal of Biological Chemistry, October 2013, American Society for Biochemistry & Molecular Biology (ASBMB)

    Dr Joshua S Savage

  31. Comment on “Platelet-Derived Nucleotides Promote Tumor Cell Transendothelial Migration and Metastasis via P2Y2 Receptor” by Schumacher et al.

    Article • Cancer Cell, September 2013, Elsevier

    Dr Joshua S Savage

  32. Munc13-4 is critical for thrombosis through regulating release of ADP from platelets

    Article • Journal of Thrombosis and Haemostasis, April 2013, Wiley

    Dr Joshua S Savage

  33. The Small GTPase Rif Is Dispensable for Platelet Filopodia Generation in Mice

    Article • PLOS One, January 2013, PLOS

    Dr Joshua S Savage

  34. Dysfunction of the PI3 kinase/Rap1/integrin  IIb 3 pathway underlies ex vivo platelet hypoactivity in essential thrombocythemia

    Article • Blood, December 2012, American Society of Hematology

    Dr Joshua S Savage

  35. Immunoblotting (Western)

    Article • November 2012, Wiley

    Dr Joshua S Savage